Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular abberations

European Journal of Cancer

Volumn 46, Issue 5, 2010, Pages 863-868

  Verweij, Jaap ^a   Baker, Laurence H ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Clinical research; Histological subtype; Molecular change; Soft tissue sarcoma; Treatment

Indexed keywords

BEVACIZUMAB; CD34 ANTIGEN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; IFOSFAMIDE; IMATINIB; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PACLITAXEL; PAZOPANIB; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TRABECTEDIN;

ANGIOSARCOMA; ARTICLE; CANCER SURVIVAL; CHROMOSOME ABERRATION; CONTINUOUS INFUSION; DRUG MECHANISM; DRUG POTENTIATION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HEMANGIOENDOTHELIOMA; HISTIOCYTOMA; HISTOPATHOLOGY; HUMAN; LEIOMYOSARCOMA; MYXOSARCOMA; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CYTOTOXINS; DERMATOFIBROSARCOMA; DISEASE PROGRESSION; GASTROINTESTINAL STROMAL TUMORS; HEMANGIOENDOTHELIOMA; HEMANGIOSARCOMA; HUMANS; LEIOMYOSARCOMA; LIPOSARCOMA, MYXOID; PIPERAZINES; PYRIMIDINES; RESEARCH DESIGN; SARCOMA; SARCOMA, SYNOVIAL; SKIN NEOPLASMS;

EID: 77349116791     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.01.016     Document Type: Article

References (62)

1. Van Glabbeke M., van Oosterom A.T., Oosterhuis J.W., et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2, 185 patients treated with anthracycline-containing first-line regimens - A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 17 (1999) 150-157
2. Sleijfer S, Ouali M, van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Le Cesne A, Hogendoorn PCW, Verweij J, Blay JYPrognostic and predictive factors for outcome to first line Ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas. An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur.J.Cancer, in pre.
3. Van Glabbeke M., Verweij J., Judson I., et al. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur. J. Cancer 38 (2002) 543-549
4. Verweij J. Soft tissue sarcoma trials: One size no longer fits all. JCO 27 (2009) 3085-3087
5. Bramwell VHC, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003;3:CD003293.
6. Göransson M., Andersson M.K., Forni C., Stahlberg A., Andersson C., Olofsson A., Aman P., et al. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ. Oncogene 28 (2009) 270-278
7. Grosso F., Jones Rl., Demetri G.D., Judon I.R., Blay J.Y., LeCesne A., Casali P., et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncology 8 (2007) 595-602
8. Erba E., Bergamschi B., Bassano L., Damia G., Ronzoni S., Faircloth G.T., and D'Incalci M. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 37 (2001) 97-105
9. Thamm D.H., Dickerson D.B., Akhtar N., Lewis R., Auerbach R., Helfand S.C., et al. Biological and molecular characterization of a canine hemangiosarcoma-derived cell line. Res Vet Sci 81 (2006) 76-86
10. Verweij J., Lee S.M., Ruka W., et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol 18 (2000) 2081-2086
11. Fata F., O'Reilly E., Ilson D., et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86 (1999) 2034-2037
12. Schlemmer M., Reichardt P., Verweij J., Hartmann J.T., Jusdon I., Thyss A., et al. Paclitaxel in patients with advance angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur. J. Cancer 44 (2008) 2433-2436
13. Saroha, Litwin S., and Von Mehren M. Retrospective review of treatment for angiosarcoma at Fox Chase Cancer Center over the past 15 years. J.Clin.Oncol. 25 Suppl. (2007) 10034
14. Nagano T., Yamada Y., Ikeda T., Kanki H., Kamo T., and Nishigori C. Docetaxel: A therapeutic option in the treatment of cutaneous angiosarcoma. Report of 9 patients. Cancer. 110 3 (2007) 648-651
15. Penel N., Bui B.N., Bay J.O., et al. Weekly paclitaxel in metastatic angiosarcoma. A FNCLCC French Sarcoma Group phase II trial. J.Clin. Oncol. 25 June 20 Suppl. (2007) 100002
16. Ng S.S., Figg W.D., and Sparreboom A. Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res. 64 3 (2004) 821-824
17. Le Cesne A., Blay J.Y., Judson I., van Oosterom A., Verweij J., Radford J., et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 23 (2005) 576-584
18. Morgan A., Le Cesne A., Chawla S., von Mehren M., Schuetze S., Casali P., et al. Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma after failure of prior anthracylines and ifosfamide. JCO 25 June 20 Supplement (2007) 10060
19. Omura G.A., Major F.J., Blessing J.A., et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52 (1983) 626-632
20. Maki R.G., Wathen J.K., Patel S.R., et al. An adaptively randomized phase II study of gemcitabine and docetaxel versus gemcitabine alone in patients with metastatic soft-tissue sarcomas. J Clin Oncol 25 (2007) 2755-2763
21. Patel S.R., Gandhi V., Jenkins J., et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19 (2001) 3483-3489
22. Spath-Schwalbe E., Genvresse I., Koschuth A., Dietzmann A., Grunewald R., and Possinger K. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anti-cancer drugs 11 (2000) 325-329
23. Okuno S., Edmonson J., Mahoney M., Buckner J.C., Frytak S., and Galanis E. Phase II trial of gemcitabine in advanced sarcomas. Cancer 94 (2002) 3225-3259
24. Svancarova L., Blay J.Y., Judson I.R., et al. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38 (2002) 556-559
25. Look K.Y., Sandler A., Blessing J.A., Lucci J.A., and Rose P.G. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecologic Oncology 92 (2004) 644-647
26. Hartmann J.T., Oechsle K., Hueber J., et al. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Investigational new drugs 24 (2006) 249-253
27. Von Burton G., Rankin C., Zalupski M.M., Mills G.M., Borden E.C., and Karen A. Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma. Am J Clin Oncol 29 (2006) 59-61
28. Hensley M.L., Maki R., Venkatraman E., et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. J. Clin. Oncol. 20 (2002) 2824-2831
29. Abbruzzese J.L., Grunewald R., Weeks E.A., et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J.Clin.Oncol. 9 (1991) :491-498
30. Smorenburg C.H., Sparreboom A., Bontenbal M., and Verweij J. Combination chemotherapy of the taxanes and antimetabolites: its use and limitations. Eur J Cancer 37 18 (2001) 2310-2323
31. Leu K.M., Ostruszka L.J., Shewach D., Zalupski M., Sondak V., Biermann J.S., et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol. 22 (2004) 1706-1712
32. F. Duffaud, B. N. Bui, N. Penel, A. Cioffi, N. Isambert, J. Y. Blay, D. Cupissol, M. Jimenez, A. Rey, P. Pautier. A FNCLCC French Sarcoma Group--GETO multicenter randomized phase II study of gemcitabine versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcoma. J Clin Oncol 2008; 26 (May 20 suppl.): abstr 10511.
33. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279 (1998) 577-580
34. Miettinen M., Sarlomo-Rikala M., Sobin L.H., et al. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol 24 (2000) 1339-1352
35. Verweij J., van Oosterom A.T., Blay J.-Y., et al. Imatinib (STI-571) is an active agent for gastro-intestinal stromal tumors, but does not yield responses in other soft tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur. J. Cancer 39 (2003) 2006-2011
36. Demetri G., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 347 (2002) 472-480
37. Verweij J., Casali P., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial. Lancet 364 (2004) 1127-1134
38. Blanke C.D., Rankin C., Demetri G.D., et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatis gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26 4 (2008) 626-632
39. Debiec-Rychter M., Sciott R., LeCesne A., et al. KIT mutations and dose selection for imatinib in patients with advances gastrointestinal stromal tumours. Eur.J.Cancer 42 (2006) 1093-1103
40. The GIST Meta-Analysis group (MetaGIST): Optimal doses of imatinib for the treatment of advanced GIST: meta-analysis on 1640 patients. J.Clin. Oncol, 2009: in press.
41. Nielsen O.S., West R.B., Linn S.C., et al. Molecular characterisation of soft tissue tumours: a gene expression study. The Lancet 359 (2002) 1301-1307
42. Ray-Coquard I., LeCesne A., Whelan J.S., et al. A phase II study of Gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. The Oncologist; 13 (2008) 467-473
43. Korkolis D.P., Liapakis I.E., and Vassilopoulos P.P. Dermatofibrosarcoma protuberans: Clinicopathological aspects of an unusual cutaneous tumor. Anticancer Res 27 (2007) 1631-1634
44. Linn S.C., West R.B., Pollack J.R., Zhu S., Hernandez-Boussard T., Nielsen T.O., et al. Gene expression pattern and gene copy number changes in dermatofibrosarcoma protruberans. Am J Pathol. 163 (2003) 2383-2395
45. Heinrich M.C., Joensuu H., Demetri G.D., Corless C.L., Apperley J., Fletcher J.A., et al. Open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res. 14 (2008) 2717-2725
46. S. Schuetze, P. Rutkowski, M. M. Van Glabbeke, C. Rankin, B. P. Rubin, A. Lazar, M. Debiec-Rychter, H. Gelderblom, P. Hohenberger, A. T. van Oosterom, Combined analysis of two phase II trials of imatinib in advanced dermatofibrosarcoma protuberans (DFSP). J Clin Oncol 2009; 27: (suppl); abstr 10520.
47. Lebbe C., Kerob R., Porcher R., et al. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: Results of a multicentric phase II study on 25 patients. J.Clin.Oncol. 25 June 20 Suppl. (2007) 10032
48. M. Agulnik, S. H. Okuno, M. Von Mehren, B. Jovanovic, B. Brockstein, R. S. Benjamin, A. M. Evens: An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma. J Clin Oncol 2009; 27 (suppl): abstr 10522.
49. Hoekstra R., de Vos F.Y., Eskens F.A., et al. Phase I safety, pharmacokinetic and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J. Clin. Oncol. 23 (2005) 5188-5197
50. Gordon M.S., Mendelson D., Carr R., et al. A phase I trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer. Cancer 113 (2008) 3420-3429
51. Baker L.H., Rowinsky E.K., Mendelson D., et al. Randomized phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol. 26 (2008) 5583-5588
52. Sleijfer S., Ray-Coquard I., Papai Z., et al. Pazopanib, a multi-kinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC study 62043): J Clin. Oncol 27 (2009) 3126-3132
53. Maki R.G., D'Adamo D.R., Keohan M.L., et al. A phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin. Oncol 27 (2009) 3133-3140
54. George S., Merriam P., Maki R.G., et al. A phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin. Oncol. 27 (2009) 3154-3160
55. Gusterson B., Cowley G., McIlhinney J., et al. Evidence for increased epidermal growth factor receptors in human sarcomas. Int J Cancer 36 (1985) 689-693
56. Wallenius V., Hisaoka M., Helou K., et al. Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors. Am J Pathol 156 (2000) 821-829
57. Motoi T., Ishida T., Kuroda M., et al. Coexpression of hepatocyte growth factor and c-Met proto-oncogene product in synovial sarcoma. Pathol Int 48 (1998) 769-775
58. Kuhnen C., Tolnay E., Steinau H.U., et al. Expression of c-Met receptor and hepatocyte growth factor/scatter factor in synovial sarcoma and epithelioid sarcoma. Virchows Arch 432 (1998) 337-342
59. Gerharz C.D., Ramp U., Reinecke P., et al. Analysis of growth factor-dependent signalling in human epithelioid sarcoma cell lines. Clues To the role of autocrine, juxtacrine and paracrine interactions in epithelioid sarcoma. Eur J Cancer 36 (2000) 1171-1179
60. Scappaticci F.A., and Marina N. New molecular targets and biological therapies in sarcomas. Cancer. Treat.Rev 27 (2001) 317-326
61. Hartog H., Wesseling J., Boezem H.M., and Van der Graaf W.T. The insulin-like growth factor 1 receptor in cancer: Old focus, new futures. Eur.J. Cancer 43 (2007) 1895-1904
62. Chugh R., Wathen J.K., Maki R.G., et al. Phase II Multicenter Trial of Imatinib in 10 Histological Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model. J Clin.Oncol 27 (2009) 3148-3153